Leading oncology experts come together for an in-depth virtual roundtable on immunotherapy strategies in advanced or metastatic melanoma. Moderated by Dr. Douglas B. Johnson of Vanderbilt University Medical Center, and joined by distinguished panelists Dr. Ahmad Tarhini (Moffitt Cancer Center) and Dr. Yana G. Najjar (University of Pittsburgh Medical Center), the series explores the evolving treatment landscape with a focus on real-world application, efficacy, and patient safety.
Panelists discuss the current treatment landscape of ES-SCLC, review recent clinical trials, and how they prepare their sites for tarlatamab administration, patient monitoring and management of adverse events
Panelists discuss how enhancing diagnostic accuracy, optimizing multidisciplinary care, and advancing treatment strategies—including targeted therapies—can improve outcomes and decision-making in patients with advanced epithelioid sarcoma (ES).
Panelists discuss how the evolving treatment landscape in relapsed/refractory follicular lymphoma, particularly in the third-line setting and beyond, is shaping clinical decision-making through patient-centered strategies that balance efficacy, tolerability, and individualized care.
Jason Efstathiou, MD, DPhil, FASTRO, FACRO; Brandon Mancini, MD, MBA, FACRO; Comron Hassanzadeh, MD, MPH; and Bridget Koontz, MD, FASTRO, discuss the evolving role of PSMA PET imaging in prostate cancer, examining its impact on diagnosis, disease staging, treatment decisions, and posttreatment assessment. They also review key clinical trial data, current guideline recommendations, and real-world applications of PSMA PET imaging in practice.
Krish Patel, MD; Saurabh Dahiya, MD, FACP; Nathan Denlinger, DO, MS; Mohamed M. Hegazi, MD, and Samuel Yamshon, MD discuss how, the DLBCL treatment landscape has evolved with CAR-T therapies transforming outcomes in R/R cases. Key considerations include risk stratification, optimal sequencing, and real-world efficacy vs. trial data. Future advances may refine patient selection, enhance manufacturing, and integrate novel therapies for improved durability and safety.
Panelists discuss how a patient-centered approach, shared decision-making, and clear communication between physicians, patients, and caregivers are essential in improving care, treatment adherence, and long-term management for individuals with paroxysmal nocturnal hemoglobinuria (PNH).
This program was made possible with support from Novartis Pharmaceuticals.
Panelists discuss how evolving treatment options, including T-DXd and tucatinib-based regimens, are reshaping the management of HER2+ metastatic breast cancer in later-line settings, emphasizing the importance of personalized therapy and proactive toxicity management.
Panelists discuss how the CAR-T referral process for relapsed/refractory multiple myeloma involves careful patient selection, bridging therapy, and coordination between community and academic centers to optimize treatment outcomes.
Cristina Gasparetto, MD; Amandeep Godara, MBBS; Ken Shain, MD, PhD; and Mansi Shah, MD, examine evolving treatment paradigms in newly diagnosed multiple myeloma (NDMM), highlighting the increasing role of daratumumab-based regimens across the care spectrum—from induction through maintenance—supported by landmark trials like PERSEUS, CASSIOPEIA, and AURIGA that demonstrate improved outcomes with these approaches while considering patient-specific factors in treatment selection.
Al-Ola Abdallah, MD; Muhammad Umair Mushtaq, MD; Jeries Kort, MD; and Zahra Mahmoudjafari examine the evolving landscape of chimeric antigen receptor (CAR) T-cell therapy in earlier lines of treatment for relapsed/refractory multiple myeloma, exploring institutional challenges around patient selection, slot availability, referral processes, and decision-making frameworks while considering both clinical and practical factors that influence treatment sequencing and access.
Panelists discuss how emerging treatment strategies, including novel induction therapies, maintenance regimens, and bispecific antibodies, are reshaping the management of newly diagnosed and relapsed/refractory multiple myeloma, with insights from ASH 2024 data and ongoing trials.
Panelists discuss how the evolving landscape of targeted therapies for PIK3CA-mutated HR+ HER2- breast cancer, including the approval of inavolisib and the growing importance of biomarker testing, is reshaping treatment strategies, patient care, and adverse event management.
Alfred Garfall, MD; Omar Nadeem, MD; Naresh Bumma, MD; and Surbhi Sidana, MD,explore the evolving therapeutic landscape of relapsed/refractory multiple myeloma, including bispecific antibodies, real-world outcomes across treatment settings, optimal sequencing strategies after CAR T progression, and long-term efficacy data from key clinical trials like MajesTEC-1.
Saad Usmani, MD, MBA; Carlyn Rose Tan, MD; Sham Mailankody, MBBS, and Sridevi Rajeeve, MD, examine evolving chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma, discussing recent clinical trial data for cilta-cel and ide-cel, comparing study outcomes, evaluating institutional implementation factors, and assessing patient eligibility criteria for optimal therapy selection in earlier treatment lines.
Panelists discuss how the introduction of bispecific antibodies is transforming the treatment landscape for relapsed/refractory multiple myeloma, addressing unmet needs and improving patient outcomes through innovative combination strategies and sequencing approaches.
Medical experts explore the optimization of patient referrals for bispecifics and CAR-T therapies through academic and community collaborations, addressing referral processes, challenges, and practical strategies with insights.
Medical experts offer insights on distinguishing RCC renal cell carcinoma (RCC) subtypes, evolving treatments, and personalized strategies for advanced non–-clear cell RCC.
A panel of experts on chronic myeloid leukemia have a comprehensive discussion on patient-centered care and the important role of shared decision-making in the optimal treatment of patients with CML.
This program was made possible with support from Novartis Pharmaceuticals.
Key opinion leaders explore the integration of circulating tumor DNA and minimal residual disease assessments into clinical practice for colorectal cancer management, discussing current applications and future prospects.
Following the 2024 ASCO Annual Meeting, a panel of experts on multiple myeloma review recent updates and discuss evolving treatment practices.
A panel of medical oncologists have a comprehensive discussion on MRD testing and the utility of ctDNA in the management of colorectal cancer, highlighting clinical trial updates from ASCO GI 2024.
Experts from Mayo Clinic offer insights into the treatment and management of CLL, highlighting key updates presented at ASH 2023 and their potential implications on the overall treatment landscape.
Experts discuss the treatment of HER2+ metastatic breast cancer through the lens of three patient cases, sharing management strategies for treatment-related adverse events and highlighting key data informing treatment decisions.
In the context of recent data updates from the WCLC and ESMO 2023 meetings, expert oncologists discuss therapy for non-small cell lung cancer with a focus on EGFR-mutant disease.
A panel of experts discusses the evolution of biomarker testing in colorectal cancer and recent key data from the MOUNTAINEER and DESTINY-CRC01 trials that are shaping the management of HER2-positive metastatic colorectal cancer through the lens of two patient case studies.
Experts discuss recent updates in the treatment of patients with relapsed/refractory multiple myeloma, share insights, and review clinical scenarios.
Leading experts discuss cutting-edge advancements in relapsed/refractory multiple myeloma treatment, including CAR T-cell therapy, bispecifics, and strategies for managing treatment-related adverse events to improve patient outcomes.
A panel of medical oncologists offer comprehensive insights on the treatment landscape for relapsed/refractory multiple myeloma and the role of bispecific antibody therapy.
